Evidence from current practice provided by NHS England and analysed by NICE indicates that digital therapies recommended for PTSD could save over 5,000 hours of therapist time per 1,000 people. Almost ...
There is a simple discount patient access scheme for rucaparib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
Rucaparib is recommended, within its marketing authorisation, as an option for the maintenance treatment of relapsed platinum-sensitive high-grade epithelial, ovarian, fallopian tube or primary ...
Rucaparib (Rubraca) is available on the NHS. It is a possible maintenance treatment for relapsed platinum-sensitive high-grade epithelial, ovarian, fallopian tube or primary peritoneal cancer that has ...
The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by the lead team of committee A, which includes the chair and vice chair. Committee members ...
10395 - Aprocitentan for treating resistant hypertension TS ID 10395 Technology appraisal guidance Abatacept for treating active idiopathic inflammatory myopathies TS ID 10095 Technology appraisal ...
Rucaparib (Rubraca, Pharm&) is indicated 'as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary ...
Section 7 of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires integrated care ...
Suggested remit: To appraise the clinical and cost effectiveness of zuranolone within its marketing authorisation for treating severe postnatal depression.
You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...
We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.